.After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on everyone market.The Eli Lilly-partnered biotech intend to list on the Nasdaq under the symbol “BIOA,” depending on to records filed with the Securities as well as Substitution Compensation. The provider has certainly not publicly shared an expected monetary volume for the offering.The clinical-stage provider proclaims lead candidate azelaprag, an orally provided small molecule slated to enter period 2 screening in combination with semaglutide– marketed by Novo Nordisk under brand name Wegovy for weight management– in the 1st fifty percent of following year. Semaglutide is additionally sold as Ozempic and Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually created to integrate effectively along with GLP-1 medicines, enhancing weight loss while preserving muscular tissue mass. The investigational medicine was actually located to be well-tolerated amongst 265 individuals across 8 phase 1 trials, according to BioAge.Formerly, BioAge amassed the help of Lilly to manage a test integrating azelaprag with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetic issues as Mounjaro as well as Zepbound for weight-loss. The companions are currently conducting a phase 2 trial of azelaprag and also tirzepatide, with topline outcomes assumed in the third quarter of 2025.The biotech is actually additionally planning a the hormone insulin level of sensitivity proof-of-concept test examining azelaprag as a monotherapy in the 1st half of next year to assist potential sign growth.
Additionally, the business prepares to ask the FDA for approval in the second half of 2025 to launch human screening for an NLRP3 prevention targeting metabolic ailments as well as neuroinflammation.BioAge’s expected move to everyone market observes a small uptick in intended biotech IPOs from Bicara Therapies and Zenas Biopharma. Zooming out, the latest IPO yard is actually a “blended photo,” with high quality business still debuting on everyone markets, only in reduced varieties, depending on to PitchBook.